Curaleaf Holdings, Inc.

Curaleaf Holdings, Inc. announced the results of its 2026 annual general and special meeting of shareholders. Key approvals include the plan of arrangement to continue the Company out of British Columbia to Delaware, and an amendment to the articles to remove the automatic conversion feature of Multiple Voting Shares. Shareholders also approved an Option Exchange Program for up to 10,070,478 stock options and elected all seven director nominees.

Curaleaf Holdings announced the filing of a supplement to its management information circular for the upcoming Annual and Special Meeting on June 22, 2026. The supplement provides additional disclosure regarding a proposed special resolution to amend the company's articles, removing the automatic conversion trigger for multiple voting shares beneficially owned by CEO Boris Jordan. This amendment would prevent the dual-class share structure from automatically terminating upon a U.S. national securities exchange listing. The company has also extended the proxy cut-off time to June 18, 2026, and encourages all shareholders to vote.

Curaleaf Holdings, Inc. announced the completion of a 1-for-3 reverse stock split of its issued and outstanding subordinate voting shares, effective June 5, 2026. Concurrently, the company also consolidated its multiple voting shares at the same 1-for-3 ratio to maintain relative shareholder rights. This action reduced the number of outstanding subordinate voting shares from approximately 698.7 million to 232.9 million.

Curaleaf Holdings, Inc. confirmed that its previously announced 1-for-3 reverse stock split of subordinate voting shares will become effective on June 5, 2026. This action will reduce the company's outstanding subordinate voting shares from approximately 698.7 million to about 232.9 million. Additionally, a concurrent 1-for-3 consolidation of multiple voting shares will occur to maintain relative shareholder rights. Registered shareholders will receive a letter of transmittal, while beneficial shareholders should contact their intermediaries.

Curaleaf Holdings, Inc. announced a 1-for-3 reverse stock split of its subordinate voting shares, effective around June 5, 2026. This strategic move, approved by the Board of Directors and conditionally approved by TSX, is designed to prepare the company for uplisting to a major U.S. stock exchange. The split aims to increase the per-share trading price, meet U.S. exchange share price criteria, and broaden institutional investor participation, anticipating greater clarity on cannabis regulatory and tax frameworks.

Curaleaf Holdings, Inc. announced its Annual General and Special Meeting (AGSM) will be held virtually on June 22, 2026. Key proposals for shareholder consideration include a significant Plan of Arrangement to re-domicile the company from British Columbia, Canada, to Delaware, USA, and an Option/RSU Exchange program for up to 10,070,478 outstanding stock options. Shareholders will also vote on the election of ten directors, the appointment of BDO USA, P.C. as auditors, approval of the 2018 Stock and Incentive Plan, and an amendment to the company's articles regarding share capital. The record date for voting is May 5, 2026, with a proxy submission deadline of June 18, 2026.

Curaleaf Holdings, Inc. announced a change in its independent auditor. PKF O Connor Davies, LLP resigned effective May 6, 2026, at the company's request. BDO USA, P.C. has been appointed as the successor auditor, a decision approved by the Board of Directors. The company confirmed that the former auditor had not expressed any modified opinions and no "reportable event" occurred.

Curaleaf Holdings, Inc. reported strong first quarter 2026 results, with net revenue increasing 6% year-over-year to $324.2 million, exceeding guidance. The company achieved a net income of $69.8 million, or $0.09 per share, a significant improvement from a net loss in the prior year. Operational highlights include the full acquisition of its German subsidiary, Four20 Pharma, and the filing of applications for DEA registration, alongside strategic debt refinancing.

Curaleaf Holdings, Inc. announced the appointment of Torsten Greif to its Board of Directors. Mr. Greif is a respected entrepreneur and a founder of Four 20 Pharma GmbH, Curaleaf's key German brand, bringing extensive expertise in cannabis cultivation and regulatory strategy. His appointment is expected to be a significant asset as Curaleaf continues to scale its European operations and integrate its European footprint.

Curaleaf Holdings, Inc. has completed the acquisition of the remaining 45% stake in Four 20 Pharma GmbH, a leading German medical cannabis producer and distributor. This full buyout strengthens Curaleaf's vertically integrated global supply chain, enhancing its presence in the European medical cannabis market. The company aims to expand the Four 20 brand internationally, building on its success in Germany and existing launches in the UK and Poland.